Glucobose

Quick links to important sections

Glucobose

Treatment option: Diabetes Mellitus

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glucobose

Quick Facts

Property Description
Active ingredient Acarbose (C25H43NO18)
Form Oral formulation (Tablet)
Pharmacological class Alpha-glucosidase inhibitor
General purpose Support glycemic control (blood sugar management)
Origin Synthetic compound (Derived from microbial fermentation)

What Type of Medicine is Glucobose?

Glucobose is a prescription-only medication defined by its active ingredient, Acarbose. It is chemically classified as a pseudotetrasaccharide and belongs to the alpha-glucosidase inhibitor pharmacological class. This classification identifies Acarbose as a component among antidiabetic drugs focused on modulating how the body processes carbohydrates.

The drug is a single-ingredient product utilized as an antihyperglycemic agent. Its specialized action is enteric-acting, which differentiates its function from other agents that target systemic insulin release or sensitivity.

Composition, Form, and General Purpose

The Glucobose product is formulated as an oral formulation in the form of a tablet, intended for oral administration. Its composition includes the active substance Acarbose and necessary solid pharmaceutical excipients. While derived from microbial sources, its finalized structure is chemically classified as a synthetic compound.

The general purpose of Glucobose is to support stable glycemic control. It achieves this by causing a delayed sugar release from consumed starches. This mechanism helps to mitigate the sharp post-meal elevation in blood sugar known as postprandial hyperglycemia, thereby promoting a more consistent metabolic profile.

Regulatory References

  1. NIH DailyMed
  2. Acarbose DailyMed Label

What side effects are possible with Glucobose?

Possible Side Effects and Safety Information

The official regulatory safety profile for Glucobose (mathbfAcarbose) is predominantly defined by effects on the gastrointestinal system, as documented in authoritative sources like the EMA Summary of Product Characteristics (SmPC) and FDA labeling.

Frequency-Classified Adverse Reactions

The frequency of side effects is categorized according to established regulatory standards:

Classification Adverse Reaction (System-Organ Class)
Very Common Flatulence (Gastrointestinal disorders)
Common Diarrhea, Abdominal pain (Gastrointestinal disorders)
Uncommon Nausea, Vomiting, Increase in hepatic transaminases (Hepatobiliary disorders)
Rare Jaundice, Hepatitis (Hepatobiliary disorders)

Serious Adverse Reactions and Restrictions

Postmarketing surveillance reports have included instances of serious events, such as Fulminant Hepatitis, and specific severe gastrointestinal conditions, including Ileus/Subileus (intestinal obstruction). Regulatory documents also list potential drug hypersensitivity reactions.

Specific safety restrictions apply to certain populations. The medicine is contraindicated for individuals with severe renal impairment (creatinine clearance <25 ml/min) and those with pre-existing severe chronic intestinal diseases. Safety and efficacy have not been established in pediatric patients (lt 18 years of age), and use during pregnancy and lactation is contraindicated.

Safety Patterns and Monitoring

The most frequent gastrointestinal adverse reactions tend to be most pronounced early in the treatment course and often lessen with continued use. Monitoring of liver enzymes (transaminases) is recommended, particularly during the initial 6 to 12 months of therapy. While Glucobose used alone does not cause hypoglycemia, combining it with insulin or sulfonylurea increases the risk of hypoglycemia.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Glucobose (mathbfAcarbose) overdose establishes two categories of concern: transient gastrointestinal effects and potential severe systemic outcomes.

Documented Manifestations and Serious Outcomes

Classification Official Regulatory Statement
GI Manifestations Overdose, particularly when ingested with carbohydrate-containing food, results in transient, increased diarrhea, flatulence, abdominal discomfort, and tympanism (distension).
Severe Outcomes Massive overdose has been associated with elevated hepatic transaminases (liver enzymes) and the potential for severe hypoglycemia, especially when used with other blood sugar-lowering agents.

Regulator-Mandated Emergency Actions

If an overdose is suspected, seek emergency medical attention immediately, or contact the Poison Help line. No specific antidote is listed in regulatory documentation; management is strictly symptomatic and supportive.

Immediate procedural steps detailed in the label include:

  • Avoid all carbohydrate-containing foods and/or drinks for the next 4–6 hours following the overdosage to limit further intestinal effects.
  • Severe hypoglycemia requires advanced supportive care, such as intravenous glucose infusion or glucagon injection, necessitating hospital monitoring.

Immediately call emergency services (911) if the individual shows signs of a life-threatening event, such as collapse, seizure, trouble breathing, or inability to be awakened.

Therapeutic Uses of Glucobose

What Glucobose treats: Main Uses and Benefits

Glucobose (Acarbose) is generally used alongside diet and exercise to improve blood sugar control in adults with Type 2 Diabetes Mellitus. It is applied across therapeutic domains where additional symptomatic support is needed to manage symptoms related to systemic imbalance. The medication is considered relevant for use in conditions characterized by periods of heightened symptoms, including managing established Type 2 Diabetes and in scenarios to support individuals with Impaired Glucose Tolerance (pre-diabetes).


The medication is commonly used to help with symptoms associated with acute or episodic changes, often applied in managing the abrupt and significant increase in blood glucose levels that may follow eating. By playing a role in managing this specific pattern, the medication assists with easing the impact of symptoms related to heightened physiological activity. Glucobose may be part of symptomatic management in situations where patients experience increased discomfort or tension. This supportive relief helps maintain a sense of functional stability and may help patients cope more steadily with symptom fluctuations.


Quick Fact Supportive Relief Focus
Symptom Target Symptoms related to systemic imbalance after meals
Use Context Applied in scenarios where additional management of discomfort is required
Primary Benefit Provides support that helps ease the overall symptom burden

Eligibility and Restrictions for Use

Glucobose eligibility is strictly defined by regulatory documents, distinguishing between approved use, formal contraindications, and populations for whom use is not recommended.


Approved and Restricted Populations

The approved use for Glucobose is limited to adults (mathbfgeq 18 years). Use in older adults is permitted with no mandatory adjustment to the standard adult regimen. The medicine is not recommended for the pediatric population (under 18 years of age) because its safety and efficacy have not been established. Furthermore, use is not recommended or contraindicated for both pregnant individuals and nursing mothers due to a lack of sufficient clinical data.


Absolute Contraindications

Glucobose is contraindicated in several specific patient groups, meaning its use is absolutely prohibited. These include individuals with known hypersensitivity to the drug, pre-existing diabetic ketoacidosis, and conditions leading to severe hepatic impairment, such as liver cirrhosis. Use is also strictly prohibited in patients with severe renal impairment (creatinine clearance mathbf< 25 mL/min) and those with chronic intestinal diseases, including inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Glucobose's documented interaction profile focuses primarily on its effect on glucose control and its mechanism of action in the gastrointestinal tract, as described in official regulatory labeling.

Pharmacodynamic Interactions

Co-administered Product Category Resulting Effect Constraint/Requirement
Other Anti-Diabetic Agents (e.g., Insulin, Sulfonylureas) Enhanced blood-glucose lowering effect. May necessitate a reduction in the dosage of the co-administered anti-diabetic agent.

Pharmacokinetic and Local Interactions

Interacting Product Category Resulting Effect Constraint/Requirement
Digestive Enzymes (e.g., Pancreatin) and Intestinal Adsorbents (e.g., Charcoal) Potential reduction in Glucobose's therapeutic effect. Co-administration is generally not recommended.
Digoxin, Metformin May alter the bioavailability or plasma concentrations of the co-administered drug. Monitoring or dosage adjustment of the co-administered drug may be required.
Warfarin Isolated reports of changes in INR (International Normalized Ratio). Close monitoring of INR is required when initiating or discontinuing Glucobose.

Food and Timing Considerations

Glucobose inhibits the breakdown of sucrose (cane sugar). Therefore, in the event of low blood sugar, only pure glucose (dextrose) should be used immediately to correct the condition, as sucrose will not be rapidly absorbed.

Mechanism of Action

Enzyme Inhibition and Carbohydrate Breakdown Delay

This mechanistic domain describes how Glucobose acts locally within the small intestine as a competitive, reversible inhibitor of alpha-glucosidase enzymes. By binding to these targets, the drug slows the breakdown of complex carbohydrates into glucose, initiating the cascade that modulates post-meal blood sugar levels. This delay in delivery is the key physiological step, which attenuates the rapid influx of sugar into the bloodstream following a meal.


Post-meal Glucose Dynamics Modulation

The primary physiological consequence of the enzyme inhibition is the delayed and reduced rate of glucose absorption from the gut into the bloodstream. This mechanistic action results in an attenuation of the postprandial glucose peak. The glucose curve is smoother and lower because the sugar enters the circulation over a prolonged duration. This gradual entry of glucose modulates the immediate glucose response following consumption.


Localized Peripheral Action

Glucobose's action is classified as peripheral, meaning its effects are largely confined to the gastrointestinal tract and are not reliant on systemic absorption or modulation of hormonal pathways (like insulin secretion) or central signaling. This mechanistic domain results in the modulation of metabolic input kinetics driven by rapid glucose loading. This targeted, localized interference with glucose delivery defines the resulting kinetic change in blood glucose.

Dosage and Administration Information

Glucobose (acarbose) is administered solely by the oral route as a standard tablet for continuous, long-term management. The medicine is utilized as an adjunct used alongside prescribed diet and exercise regimens.

Administration Scope and Regimen

Parameter Usage Principle
Route and Form Oral administration as a standard tablet.
Timing Must be taken at the start (with the first bite) of each main meal.
Initial Dose Typically begins at 25 mg three times daily (t.i.d.).
Maintenance Dose The dose is gradually increased in 4 to 8 week intervals, reaching a common maintenance range of 50 mg to 100 mg t.i.d..
Maximum Dose The maximum recommended dosage specifies a limit of 100 mg t.i.d. for patients over 60 kg.

Procedural Structure and Adjustments

The established protocol requires a precise use pattern tied directly to food consumption. If a dose is missed, the medicine should not be taken between meals; the patient should resume the schedule with the next main meal.

Usage guidelines for specific populations are defined: The usual adult dose is generally applied to older adults (65 years and older) without mandatory modification based on age. However, use in pediatric patients (under 18 years) is not recommended due to a lack of established clinical data.

This structured regimen defines the standardized continuous treatment, requiring three daily administrations synchronized with the beginning of food consumption.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Glucobose

This section provides a summary of the research conducted on Glucobose (Acarbose), explaining the types of studies available, the outcomes they monitored, and the areas where information is still emerging or limited. Research findings describe group patterns and should not be used to predict individual outcomes.


Evidence for Use in Type 2 Diabetes Mellitus

Glucobose was studied for Type 2 Diabetes Mellitus using well-designed research, primarily Randomized Controlled Trials (RCTs) and systematic reviews that analyze data from multiple trials (meta-analyses). These studies focused on measuring how Glycosylated Hemoglobin ( HbA1c) and Postprandial Glucose (PPG, or blood sugar levels after meals) were recorded during the study period.

These studies monitored specific blood sugar markers in various groups of adults with T2DM. Research examined shifts in the measured markers, which were monitored throughout the study period. Trials also explored patterns in data collected for certain outcomes related to cardiovascular health. However, data show patterns related to cardiovascular outcomes were sometimes mixed or inconsistent across the assembled evidence, meaning certainty remains low for these specific long-term findings.


Evidence for Use in Impaired Glucose Tolerance (Pre-Diabetes)

Glucobose was evaluated in large-scale, long-term clinical trials focusing on individuals with Impaired Glucose Tolerance (IGT), often referred to as pre-diabetes. This research examined the incidence of progression to a formal diagnosis of Type 2 Diabetes Mellitus over the study period.

These studies monitored the overall rate of progression and also looked at secondary outcomes, such as measurements related to vascular health and the incidence of new cases of high blood pressure (hypertension). Studies monitored the data regarding the rate of progression to a T2DM diagnosis in the observed populations. Evidence from secondary analyses describes data collected for cardiovascular outcomes in some long-term studies.


What is Still Uncertain About Glucobose Research

The research on Glucobose has provided context regarding its use in monitoring blood sugar and its association with T2DM progression, but several areas remain uncertain. Long-term outcomes related to vascular outcomes and mortality are not yet well characterized, as evidence quality varies across studies and findings were sometimes mixed. There is also uncertainty regarding the impact of high dropout rates observed in some clinical trials, which means results apply only to the populations studied and may not fully reflect outcomes if long-term adherence were higher.

Frequently Asked Questions (FAQ)

Common questions about Glucobose (FAQ)

Q: How fast does Glucobose start working after you take it?

A: Glucobose acts locally within the intestine to delay carbohydrate absorption. Regulatory information indicates that the minimal amounts of the active substance that are absorbed into the bloodstream generally reach their highest concentration about one to two hours after administration.

Q: Can Glucobose cause low blood sugar?

A: According to the official product information, Glucobose is not typically associated with causing hypoglycemia (low blood sugar) when used as a single agent. However, if Glucobose is taken in combination with other anti-diabetic agents, such as insulin or sulfonylureas, the risk of low blood sugar is increased.

Q: What foods should I avoid when taking Glucobose?

A: Regulatory information advises that Glucobose works by inhibiting the breakdown of sucrose, which is common table sugar. Therefore, in a situation of low blood sugar, it is indicated that only pure glucose (dextrose) should be used, because the drug's action prevents the rapid absorption of sucrose.

Q: Can I drink alcohol while I'm on Glucobose?

A: Official patient counseling for diabetes management suggests that consuming excessive alcohol may interfere with the body's ability to control blood glucose levels. Consultation with a healthcare provider regarding alcohol consumption is generally recommended for individuals managing diabetes with this or any other medication.

Q: Does Glucobose interact with blood pressure medicine?

A: The drug label highlights that certain types of medications, including some diuretics (water pills) often used for blood pressure, may affect blood glucose control. These changes could potentially reduce the therapeutic effectiveness of Glucobose. It is important that healthcare providers are informed of all current medications to assess potential interactions.

Q: What happens if I miss a dose of Glucobose?

A: Official guidance states that if a dose of Glucobose is missed, it should not be taken between meals. Instead, the patient should simply wait and resume the scheduled medication pattern with the next main meal.

Q: Can Glucobose be taken with pain relievers like ibuprofen?

A: Regulatory labeling advises patients to discuss the use of nonprescription medicines, including pain relievers, with a healthcare provider. Drug labels contain general warnings about co-administering Glucobose with other nonprescription medications.

Q: Does Glucobose have any effects on the liver?

A: Yes, official safety data notes that uncommon increases in liver enzymes (hepatic transaminases) have been reported, as have rare but more serious events like jaundice or hepatitis. Due to these potential effects, monitoring of liver enzymes is specifically recommended, particularly during the first 6 to 12 months of therapy.

Q: Does Glucobose help prevent long-term complications of diabetes?

A: Studies and official information indicate that clinical trials monitored outcomes related to vascular health and diabetes progression. However, data regarding long-term outcomes and mortality are currently not fully consistent or well-characterized across all available studies.

Q: Can Glucobose affect my energy levels?

A: The regulatory documents, including post-marketing surveillance reports, have noted that some patients experience symptoms such as unusual weakness or fatigue. These symptoms may also be related to blood sugar fluctuations.

Q: Is it normal to feel nauseous when starting Glucobose?

A: Nausea is classified as an uncommon side effect in official safety profiles. The regulatory text suggests that common gastrointestinal side effects often tend to be most noticeable early in the treatment course and may lessen with continued use of the medication.

Q: Do I need to change my diet drastically when taking Glucobose?

A: Glucobose is officially indicated as an adjunct, meaning it is prescribed to be used alongside a controlled diet and exercise regimen. It is designed to work as part of a comprehensive lifestyle management plan.

Q: Can Glucobose cause stomach problems or gas?

A: Yes, common gastrointestinal issues are frequent with Glucobose. According to regulatory safety profiles, flatulence (gas) is classified as a Very Common side effect, and abdominal pain is classified as a Common side effect.

Q: Does Glucobose interact with herbal supplements?

A: Official drug labeling advises against taking other medications or supplements, including herbal products, without first consulting a healthcare provider. This is generally advised because some herbal supplements may affect blood glucose control or the way Glucobose works.

Q: Is Glucobose ever used for conditions other than diabetes?

A: Glucobose has a very specific, approved indication. Official regulatory documents indicate the drug is approved and intended only to improve glycemic control in adults who have been diagnosed with Type 2 Diabetes Mellitus.

Q: Are there any long-term side effects associated with Glucobose?

A: Regulatory documents indicate that the most frequent gastrointestinal side effects often lessen over time with continued use. Specific long-term monitoring is advised for liver enzyme levels, particularly during the first year of therapy.

Q: Do you take Glucobose with food or on an empty stomach?

A: Official administration instructions are very precise on this point. Glucobose must be taken at the very beginning (with the first bite) of each main meal to ensure it works correctly to delay carbohydrate absorption.

Q: Can Glucobose make me feel dizzy?

A: Dizziness is not listed as a primary side effect of Glucobose itself, but it is a common symptom of low blood sugar. This may occur if Glucobose is used along with other diabetes medications or if your blood sugar is fluctuating widely.

Q: Why is my blood sugar not dropping immediately after starting Glucobose?

A: The drug is not designed to cause an immediate, rapid drop in blood sugar levels. Its mechanism is focused on slowing down the rate at which sugar enters your bloodstream after a meal, which helps prevent sharp glucose spikes over time.

Q: Does Glucobose work if I don't change my lifestyle?

A: The official therapeutic indication clearly states that the medicine is meant to be used as an adjunct—a supporting treatment—to diet and exercise. Its intended use is as part of a comprehensive lifestyle management plan.

Q: Can Glucobose affect birth control pills?

A: Official labeling contains warnings that some components of oral hormonal contraceptives may potentially interfere with blood glucose control. The potential interaction is due to the effect of hormonal contraceptives on blood glucose control itself, which may affect the overall management of diabetes.

Q: Is Glucobose considered a first-line treatment for Type 2 diabetes?

A: Glucobose is indicated as a monotherapy or combination treatment option. Clinical guidelines identify several different medications that may be used as initial therapy, and Glucobose is available as an option for improving glycemic control.

Q: How is Glucobose eliminated from the body?

A: The drug acts primarily in the gastrointestinal tract. Of the small portion that is systemically absorbed, it is mostly eliminated from the body by the kidneys as the parent drug and its breakdown products. The majority of the medicinal activity is eliminated in the feces.

Q: Are there known drug-drug interactions with common cold medications?

A: Official labeling advises caution regarding medicines that may impact blood glucose control. Certain common cold medications that contain sympathomimetic agents (such as some decongestants) may interfere with blood glucose control and could potentially reduce the therapeutic effect of Glucobose.

How should Glucobose be stored and disposed of?

Storage and Disposal Requirements for Glucobose

Glucobose (acarbose tablets) must be stored according to official regulatory specifications to maintain the product's quality and labeled stability.


Storage Conditions

Requirement Official Instruction
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze or expose to excessive heat.
Protection Keep in a dry place and protect from moisture and light.
Container Keep in the original container and ensure it is tightly closed.
Stability Do not use after the expiry date printed on the package.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Glucobose must not be thrown away with household waste or disposed of via wastewater. Patients should follow local requirements for disposal, typically by returning the medication to a pharmacy or using a medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glucobose found in:

A-Z Index: